DPT Laboratories To Integrate With Confab - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPT Laboratories To Integrate With Confab



The CDMOs DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, have integrated under the leadership of Paul Johnson, group president and COO. Both DPT and Confab are owned by Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.

The integration includes a rebranding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s sales and marketing team to introduce Confab’s experts in complex solid, semi-solid, and liquid dosage forms to new pharmaceutical industry clients, especially in the US market. The management teams for both companies will remain inplace, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson. DPT has additional R&D and manufacturing facilities in Lakewood, New Jersey.

Source: DPT Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here